Lipids & metabolic liver disease

Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes Obes MetabPublished Prospective cohort study

An erratum to this article was published (Diabetes Obes Metab, Oct 2026 ↗)

Main finding · Composite CKOResult — go to the resultAdjusted hazard ratio 1.24 95% CI 1.18–1.30

Authors' conclusion

MASLD independently predicted CKO, particularly among individuals with low IGF-1 levels.

Study context

Population
UK Biobank participants without baseline cardiovascular disease or CKDUK Biobank
Participants
214,512 participants
Exposure
MASLD stratified by age- and sex-specific IGF-1 tertiles vs no-MASLD
Outcome
Composite cardio-kidney outcome (CKO)
Follow-up
median 13-year follow-up
Methodological detailsUK Biobank, multivariable Cox models
  • UK Biobank
  • Multivariable Cox models

Main finding

Composite CKO

Adjusted hazard ratio

1.24

95% CI 1.18–1.30

MASLD T1vs no-MASLD
aHR 1.24 (95% CI 1.18–1.30)

As reported in the abstract

Cardio-kidney outcomes (CKOs) occurred
20 395
MASLD increased event rates across all IGF-1 tertiles
P < 0.001
Significant interaction between MASLD and IGF-1 levels
P for interaction = 0.014

Observational data: associations, not effects.

Secondary outcomes

OutcomeaHR (95% CI)
Incident CKD · median 13-year follow-upT1vs no-MASLDSimilar trend to CKO, MASLD in lowest IGF-1 tertile · multivariable Cox models1.35 (1.22–1.49)
3P-MACE · median 13-year follow-upT1vs no-MASLDSimilar trend to CKO, MASLD in lowest IGF-1 tertile · multivariable Cox models1.26 (1.18–1.35)

Subgroups: sex, BMI, DM, age, albuminuria

Consistent associations across sex, BMI and DM; stronger effects in participants <65 years; markedly greater CKD risk with baseline albuminuria

Original publication

Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Diabetes Obes Metab. Published 27 April 2026. doi:10.1111/dom.70792

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.